Incanthera PLC Result of GM (1733V)
12 Aprile 2021 - 1:34PM
UK Regulatory
TIDMINC
RNS Number : 1733V
Incanthera PLC
12 April 2021
12 April 2021
Incanthera plc
("Incanthera" or the "Company")
Result of General Meeting
Incanthera plc (AQSE: INC), the specialist oncology company
focused on innovative technologies in oncology and dermatology
announces the results of a General Meeting held at 11am today, in
accordance with COVID-19 guidance .
The General Meeting follows the company's announcement on 23
March 2021, of a Placing to raise GBP1.14m, including an option for
Warrants, which were subject to Shareholder approval.
The Company is pleased to announce that all resolutions were
duly passed.
The Company would like to thank all Shareholders who returned
their Proxy form and wishes all Shareholders and their families
well.
For further enquiries:
Incanthera plc
www.incanthera.com
Tim McCarthy, Chairman
tim.mccarthy@incanthera.com +44 (0) 7831 675747
Simon Ward, Chief Executive Officer
simon.ward@incanthera.com +44 (0) 7747 625506
Suzanne Brocks, Head of Communications
suzanne.brocks@incanthera.com +44 (0) 7776 234600
Aquis Exchange Corporate Adviser:
Cairn Financial Advisers LLP
Jo Turner/James Lewis +44 (0) 20 7213 0880
Broker:
Stanford Capital Partners Ltd
Patrick Claridge/John Howes/Bob Pountney +44 (0) 20 3815 8880
Notes to Editors
Incanthera is a specialist oncology company focused on
transforming cancer treatment by creating environments in which
cancer cannot survive. It seeks to identify and develop innovative
solutions to current clinical, commercially relevant unmet needs,
utilising new technology from leading academic institutions.
The Company's current lead product and focus is Sol, a
potentially innovative topical product for the treatment of solar
keratosis and the prevention of skin cancers. This has achieved
proof of concept and the Company is now focussed upon delivering
Sol to a commercial partner.
The Company originated from the Institute of Cancer Therapeutics
("ICT") at the University of Bradford and has acquired and
developed a portfolio of specific cancer-targeting therapeutics
through a Pipeline Agreement with the ICT and other corporate
acquisitions.
Incanthera's strategy is to develop each candidate in the
portfolio from initial acquisition or discovery to securing its
future through commercially valuable partnerships at the earliest
opportunity in its development pathway.
For more information on the Company please visit:
www.incanthera.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXBBGDSIDBDGBD
(END) Dow Jones Newswires
April 12, 2021 07:34 ET (11:34 GMT)
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Incanthera (AQSE:INC)
Storico
Da Apr 2023 a Apr 2024